Five-year survival in @entity1 with unresectable @entity1149 ( @entity1149 ) is less than 10%. In the present phase II study, 43 @entity1 with locally advanced stage IIIA or selected IIIB @entity1149 were given four courses of @entity3003 AUC = 6 and @entity1311 200 mg/m2 (3-hour infusion), every 3 weeks. Responsive @entity1 , when possible, underwent surgery followed by standard radiotherapy (50 Gy) or radiotherapy (60 Gy), with concurrent @entity900 as intravenous continuous infusion of 4 mg/m2/d. Sixteen of the 42 evaluable @entity1 achieved partial response (38%) and 3 complete response (CR) (7%) for an overall response rate of 45% (95% CI 30.1-60.2). R0 resectability rate was 29%, with 21% of pathologic CRs. Three more CRs were achieved with concurrent chemoradiotherapy in responsive but unresected @entity1 . Grade III/IV hematologic @entity137 was 9%, while one perioperative @entity204 occurred. The median duration of response was 14 months (range: 3-44+); median survival was 15 months (range: 9-47+). One-year and 2-year survival rates were 51% and 22%, respectively. The median survival in the responsive resected @entity1 was 26 months, with 2-year survival of 57%. @entity3003 / @entity1311 represents an effective and well-tolerated induction therapy, suggesting its possible role in combination with radiotherapy as neoadjuvant treatment in locally advanced @entity1149 in alternative to @entity900 -based regimens.

Induction chemotherapy with @entity3003 / XXXX followed by surgery or standard radiotherapy and concurrent daily low-dose @entity900 for locally advanced @entity1149 ( @entity1149 ).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
